- Source: CUMYL-PEGACLONE
CUMYL-PEGACLONE (SGT-151) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug. The gamma-carboline core structure seen in CUMYL-PEGACLONE had not previously been encountered in a designer cannabinoid, though it is similar in structure to other gamma-carboline cannabinoids disclosed by Bristol-Myers Squibb in 2001.
Legal status
Sweden's public health agency classified CUMYL-PEGACLONE as a narcotic substance, on January 18, 2019.
In the United States, the DEA has temporarily placed CUMYL-PEGACLONE into Schedule I status starting on December 12th, 2023 for up to 2 years, during which it's possible the DEA could file for permanent scheduling within those 2 years. If the DEA does not file for permanent placement the temporary Schedule I order will expire on December 12th, 2025.
See also
5F-CUMYL-PEGACLONE
CUMYL-CB-MEGACLONE
CUMYL-CH-MEGACLONE
CUMYL-BC-HPMEGACLONE-221
CUMYL-PINACA
CUMYL-5F-P7AICA
UR-12
References
Kata Kunci Pencarian:
- CUMYL-PEGACLONE
- 5F-CUMYL-PEGACLONE
- Tetrahydrocannabinolic acid
- Δ-8-Tetrahydrocannabinol
- ADB-BUTINACA
- Conversion of CBD to THC
- Effects of cannabis
- 11-Hydroxy-THC
- CUMYL-PINACA
- Brazilian Controlled Drugs and Substances Act
